Bhamidipati PK, et al. - For stem cell mobilization in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), the first prospective randomized trial compared the safety and efficacy of tbo-filgrastim in combination with plerixafor with that of filgrastim in combination with plerixafor. This study found the tbo-filgrastim and filgrastim arms similar in all secondary endpoints. As compared to reference filgrastim when used for stem cell mobilization in patients with MM and NHL, tbo-filgrastim was not inferior in efficacy and had a similar safety. Results suggested the safe use of Granix instead of Neupogen for stem cell collection in patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT) for MM or NHL.